Related Experiment Videos
DNA methylation changes in multiple myeloma.
1Medizinische Klinik IV, Universitaetsklinikum Aachen, 52074 Aachen, Germany. oliver.galm@post.rwth-aachen.de
Leukemia
|August 20, 2004
Summary
Aberrant methylation of tumor suppressor genes is common in multiple myeloma (MM). Hypermethylation of specific genes like p16 correlates with poorer prognosis and may play a role in plasma cell disorder development.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Multiple myeloma (MM) is a malignant plasma cell disorder.
- Tumor suppressor genes (TSGs) are critical in preventing cancer development.
- Epigenetic alterations, such as DNA methylation, can silence TSGs.
Purpose of the Study:
- To investigate the promoter-associated CpG island methylation status of 11 TSGs in MM.
- To determine the frequency of aberrant methylation in MM cell lines and patient samples.
- To explore the correlation between methylation patterns and clinical characteristics in MM.
Main Methods:
- Candidate gene approach analyzing 11 well-characterized TSGs.
- Methylation-specific polymerase chain reaction (MS-PCR).
- Analysis in five MM cell lines and 56 primary patient samples.
Main Results:
- At least one hypermethylated gene was found in 80.4% of patient samples; 33.9% had two or more.
- Aberrant methylation frequencies: SOCS-1 (46.4%), p16 (35.7%), E-cadherin (21.4%), DAP kinase/p73 (12.5%), p15/MGMT/RARbeta (1.8%).
- p73 hypermethylation identified in MM for the first time; p16 hypermethylation linked to poorer prognosis.
Conclusions:
- Aberrant methylation of TSGs is a frequent event in malignant plasma cell disorders.
- Specific methylation patterns, including p73, are implicated in MM pathogenesis.
- Methylation status correlates with clinical characteristics and prognosis in MM patients.